metoprolol and Aging
metoprolol has been researched along with Aging in 36 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metoprolol is a β-adrenergic receptor antagonist that is ineffective in younger patients, but may benefit older (≥40 years) VVS patients." | 6.82 | Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5). ( Benditt, DG; Faris, PD; Krahn, AD; Manns, B; Morillo, CA; Raj, SR; Semeniuk, L; Sheldon, RS, 2016) |
| " The mean hepatic clearances determined by in silico fitting for individual pharmacokinetic models of warfarin and midazolam in the aged group were, respectively, 23% and 56% smaller than those for the young group." | 5.48 | Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. ( Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H, 2018) |
| " administration of racemic metoprolol in the rat, the plasma concentrations of (R)- and (S)-metoprolol were comparable, and no differences in pharmacokinetic parameters between the two enantiomers were found." | 5.29 | Aging and the pharmacokinetics and metabolism of metoprolol enantiomers in the rat. ( Belpaire, FM; Bogaert, MG; De Smet, F; Vercruysse, I; Vermeulen, AM, 1993) |
| " administration of the beta blockers, no significant increase in area under the plasma drug concentration-time curve was observed for propranolol and metoprolol as a function of age, but for atenolol, a significant increase in area under the plasma drug concentration-time curve was seen in the 24-month-old rats, due to a decrease in renal function, as bioavailability of atenolol did not change in function of age." | 5.28 | Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat. ( Belpaire, FM; Bogaert, MG; Chauvelot-Moachon, L; de Smet, F; Rosseel, MT; Vermeulen, AM; Vynckier, LJ, 1990) |
| " The effects of aging on the responsiveness of the isolated pacemaker of the rat to the chronotropic effect of norepinephrine, isoproterenol and soterenol were studied." | 3.68 | Subsensitivity to beta-adrenoceptor agonists in pacemakers isolated from senescent rats. ( de Moraes, S; Spadari, RC, 1991) |
| "Metoprolol is a β-adrenergic receptor antagonist that is ineffective in younger patients, but may benefit older (≥40 years) VVS patients." | 2.82 | Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5). ( Benditt, DG; Faris, PD; Krahn, AD; Manns, B; Morillo, CA; Raj, SR; Semeniuk, L; Sheldon, RS, 2016) |
| " They were submitted to clinical exam, stress testing and plasma lipids dosage before and after four weeks of treatment." | 2.66 | [Effect of beta blockers with intrinsic sympathomimetic activity on blood pressure and blood lipids in patients with essential hypertension]. ( Bellotti, G; Braga, A; Pileggi, F; Santomauro, A; Serro-Azul, JB; Serro-Azul, LG; Wajngarten, M; Yazbek Júnior, P, 1989) |
| "Heart failure is associated with increased sympathetic nervous stimulation that results in down-regulation of myocardial beta-1 receptors." | 2.42 | Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. ( Ahmed, A, 2003) |
| " The mean hepatic clearances determined by in silico fitting for individual pharmacokinetic models of warfarin and midazolam in the aged group were, respectively, 23% and 56% smaller than those for the young group." | 1.48 | Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. ( Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H, 2018) |
| "Treatment with metoprolol decreased systolic blood pressure at 21 months only but improved survival, decreased ventricular weight, prevented chamber dilation, reduced inflammation, decreased fibrosis, attenuated action potential prolongation, improved systolic and diastolic function, decreased stiffness and improved endothelium-independent vascular responses." | 1.37 | Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat. ( Brown, L; Chan, V; Fenning, A; Hoey, A, 2011) |
| "A new, once-daily combination tablet containing felodipine and metoprolol has been developed, using extended-release techniques to obtain even plasma concentrations throughout the dosing interval." | 1.29 | Design and pharmacokinetics of Logimax, a new extended-release combination tablet of felodipine and metoprolol. ( Abrahamsson, B; Edgar, B; Lidman, K; Wingstrand, K, 1993) |
| " administration of the beta blockers, no significant increase in area under the plasma drug concentration-time curve was observed for propranolol and metoprolol as a function of age, but for atenolol, a significant increase in area under the plasma drug concentration-time curve was seen in the 24-month-old rats, due to a decrease in renal function, as bioavailability of atenolol did not change in function of age." | 1.28 | Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat. ( Belpaire, FM; Bogaert, MG; Chauvelot-Moachon, L; de Smet, F; Rosseel, MT; Vermeulen, AM; Vynckier, LJ, 1990) |
| " 3 Areas under the plasma concentration curve for metoprolol after repeated administration are greater than would be predicted from single dose data, and possible explanations for this are discussed." | 1.26 | The effect of age on the pharmacokinetics of metoprolol and its metabolites. ( Jack, DB; Kendall, MJ; Quarterman, CP, 1981) |
| "Propranolol did not cause this pressor effect in prehypertensive (seven week old) SHRs." | 1.26 | Beta-adrenergic receptor blocking drugs in spontaneous hypertension. ( Levy, JV, 1976) |
Research
Studies (36)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (27.78) | 18.7374 |
| 1990's | 11 (30.56) | 18.2507 |
| 2000's | 6 (16.67) | 29.6817 |
| 2010's | 8 (22.22) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Tran, T | 1 |
| Mach, J | 1 |
| Gemikonakli, G | 1 |
| Wu, H | 1 |
| Allore, H | 1 |
| Howlett, SE | 1 |
| Little, CB | 1 |
| Hilmer, SN | 1 |
| Toda, A | 1 |
| Uehara, S | 1 |
| Inoue, T | 1 |
| Utoh, M | 1 |
| Kusama, T | 1 |
| Shimizu, M | 1 |
| Uno, Y | 1 |
| Mogi, M | 1 |
| Sasaki, E | 1 |
| Yamazaki, H | 1 |
| Chatzidou, S | 1 |
| Georgiopoulos, G | 1 |
| Kontogiannis, C | 1 |
| Bratt, EL | 1 |
| Östman-Smith, I | 1 |
| Sun, Y | 1 |
| Wang, Y | 1 |
| Zhang, L | 1 |
| Xu, C | 1 |
| Liu, Y | 1 |
| Kang, S | 1 |
| Yan, C | 1 |
| Li, D | 1 |
| Sun, H | 1 |
| Raj, SR | 1 |
| Faris, PD | 1 |
| Semeniuk, L | 1 |
| Manns, B | 1 |
| Krahn, AD | 1 |
| Morillo, CA | 1 |
| Benditt, DG | 1 |
| Sheldon, RS | 1 |
| Chudzik, M | 1 |
| Maciążek-Jurczyk, M | 1 |
| Pawełczak, B | 1 |
| Sułkowska, A | 1 |
| Chan, V | 1 |
| Fenning, A | 1 |
| Hoey, A | 1 |
| Brown, L | 1 |
| Fedorets, VN | 1 |
| Dorne, JL | 1 |
| Walton, K | 1 |
| Slob, W | 1 |
| Renwick, AG | 1 |
| Ahmed, A | 1 |
| Schutzer, WE | 1 |
| Xue, H | 1 |
| Reed, JF | 1 |
| Mader, SL | 1 |
| Leosco, D | 1 |
| Rengo, G | 1 |
| Iaccarino, G | 1 |
| Filippelli, A | 1 |
| Lymperopoulos, A | 1 |
| Zincarelli, C | 1 |
| Fortunato, F | 1 |
| Golino, L | 1 |
| Marchese, M | 1 |
| Esposito, G | 1 |
| Rapacciuolo, A | 1 |
| Rinaldi, B | 1 |
| Ferrara, N | 1 |
| Koch, WJ | 1 |
| Rengo, F | 1 |
| Funovic, P | 1 |
| Korda, M | 1 |
| Kubant, R | 1 |
| Barlag, RE | 1 |
| Jacob, RF | 1 |
| Mason, RP | 1 |
| Malinski, T | 1 |
| Clark, DW | 1 |
| Morgan, AK | 1 |
| Waal-Manning, H | 1 |
| Quarterman, CP | 1 |
| Kendall, MJ | 2 |
| Jack, DB | 1 |
| de Champlain, J | 1 |
| Cousineau, D | 1 |
| Lapointe, L | 1 |
| Suh, YH | 1 |
| Lee, IS | 1 |
| Kim, SS | 1 |
| Choi, W | 1 |
| Park, CW | 1 |
| Chung, MH | 1 |
| Lim, JK | 1 |
| Abrahamsson, B | 1 |
| Edgar, B | 1 |
| Lidman, K | 1 |
| Wingstrand, K | 1 |
| Ljungman, S | 1 |
| Wikstrand, J | 3 |
| Hartford, M | 1 |
| Aurell, M | 1 |
| Lindstedt, G | 1 |
| Berglund, G | 1 |
| Vermeulen, AM | 2 |
| Belpaire, FM | 2 |
| De Smet, F | 2 |
| Vercruysse, I | 1 |
| Bogaert, MG | 2 |
| Lane, CD | 1 |
| Wan, J | 1 |
| Xie, YH | 1 |
| Xia, H | 1 |
| Lu, YQ | 1 |
| Lindahl, A | 1 |
| Krondahl, E | 1 |
| Grudén, AC | 1 |
| Ungell, AL | 1 |
| Lennernäs, H | 1 |
| Fujii, K | 1 |
| Onaka, U | 1 |
| Goto, K | 1 |
| Abe, I | 1 |
| Fujishima, M | 1 |
| Shi, X | 1 |
| Wray, DW | 1 |
| Formes, KJ | 1 |
| Wang, HW | 1 |
| Hayes, PM | 1 |
| O-Yurvati, AH | 1 |
| Weiss, MS | 1 |
| Reese, IP | 1 |
| Levy, JV | 1 |
| Watson, RD | 1 |
| Stallard, TJ | 1 |
| Littler, WA | 1 |
| Brown, D | 1 |
| Yates, RA | 1 |
| Spadari, RC | 1 |
| de Moraes, S | 1 |
| Vanscheeuwijck, P | 1 |
| Van de Velde, E | 1 |
| Fraeyman, N | 1 |
| Vynckier, LJ | 1 |
| Rosseel, MT | 1 |
| Chauvelot-Moachon, L | 1 |
| Elfellah, MS | 1 |
| Dalling, R | 1 |
| Kantola, IM | 1 |
| Reid, JL | 1 |
| Serro-Azul, JB | 1 |
| Wajngarten, M | 1 |
| Santomauro, A | 1 |
| Braga, A | 1 |
| Yazbek Júnior, P | 1 |
| Bellotti, G | 1 |
| Serro-Azul, LG | 1 |
| Pileggi, F | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects[NCT02123056] | Phase 4 | 52 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
2 reviews available for metoprolol and Aging
| Article | Year |
|---|---|
Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.
Topics: Adrenergic beta-Antagonists; Aging; Carbazoles; Carvedilol; Down-Regulation; Heart Failure; Hemodyna | 2003 |
New concepts in the treatment of elderly hypertensive patients.
Topics: Aged; Aging; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Heart Ventricles; Hum | 1988 |
Trials
3 trials available for metoprolol and Aging
| Article | Year |
|---|---|
Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Aging; Dose-Response Relationship, D | 2016 |
[Effect of beta blockers with intrinsic sympathomimetic activity on blood pressure and blood lipids in patients with essential hypertension].
Topics: Aging; Blood Pressure; Clinical Trials as Topic; Exercise Test; Female; Heart Rate; Humans; Hyperten | 1989 |
New concepts in the treatment of elderly hypertensive patients.
Topics: Aged; Aging; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Heart Ventricles; Hum | 1988 |
Other Studies
32 other studies available for metoprolol and Aging
| Article | Year |
|---|---|
Diurnal effects of polypharmacy with high drug burden index on physical activities over 23 h differ with age and sex.
Topics: Age Factors; Aging; Animals; Behavior, Animal; Cholinergic Antagonists; Circadian Rhythm; Explorator | 2022 |
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotyp | 2018 |
Implications of aging in the treatment of complex arrhythmias.
Topics: Aging; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Metoprolol; Propranolol | 2018 |
Effects of lifestyle changes and high-dose β-blocker therapy on exercise capacity in children, adolescents, and young adults with hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aging; Blood Pressure; Cardiomyopathy, Hypertrophic, | 2015 |
Prevention of cardiac events caused by surgical stress in aged rats: simultaneously activating β2-adrenoceptor and inhibiting β1-adrenoceptor.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Aging; Animals; Cardiac Surgical P | 2014 |
Spectroscopic Studies on the Molecular Ageing of Serum Albumin.
Topics: Aging; Animals; Binding Sites; Cattle; Circular Dichroism; Computer Simulation; Humans; Metoprolol; | 2016 |
Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Aging; Animals; Blood Pressure; Disease Models, Animal; Dose | 2011 |
[Ischemic heart disease in elderly patients of behavioral type A (psychosocial and clinic functional changes, possibilities for correction)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Anti-Anxiety Agents; Behavioral Symptoms; Benzodiaz | 2011 |
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoqu | 2002 |
Effect of age on vascular beta2-adrenergic receptor desensitization is not mediated by the receptor coupling to Galphai proteins.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aging; Animals; Aorta; GTP | 2006 |
Exercise training and beta-blocker treatment ameliorate age-dependent impairment of beta-adrenergic receptor signaling and enhance cardiac responsiveness to adrenergic stimulation.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aging; Animals; Blood Pres | 2007 |
Effect of beta-blockers on endothelial function during biological aging: a nanotechnological approach.
Topics: Adrenergic beta-Antagonists; Aging; Animals; Aorta, Thoracic; Arginine; Atenolol; Cellular Senescenc | 2008 |
Adverse effects from metoprolol are not generally associated with oxidation status.
Topics: Aging; Antibodies, Antinuclear; Female; Humans; Male; Metoprolol; Oxidation-Reduction; Sex Factors; | 1984 |
The effect of age on the pharmacokinetics of metoprolol and its metabolites.
Topics: Adolescent; Adult; Aged; Aging; Chemical Phenomena; Chemistry; Female; Humans; Kinetics; Metoprolol; | 1981 |
Evidences supporting an increased sympathetic tone and reactivity in a subgroup of patients with essential hypertension.
Topics: Adult; Aging; Blood Pressure; Catecholamines; Diagnosis, Differential; Epinephrine; Female; Heart Ra | 1980 |
Ligand binding characteristics of [3H] dihydroalprenolol in cerebral cortical membranes of young and old senescence-accelerated mouse.
Topics: Aging; Animals; Cerebral Cortex; Dihydroalprenolol; Male; Metoprolol; Mice; Radioligand Assay; Recep | 1993 |
Design and pharmacokinetics of Logimax, a new extended-release combination tablet of felodipine and metoprolol.
Topics: Adult; Aged; Aging; Biological Availability; Delayed-Action Preparations; Drug Combinations; Felodip | 1993 |
Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension.
Topics: Aging; Albuminuria; Case-Control Studies; Drug Therapy, Combination; Follow-Up Studies; Glomerular F | 1993 |
Aging and the pharmacokinetics and metabolism of metoprolol enantiomers in the rat.
Topics: Administration, Oral; Aging; Animals; Cytochrome P-450 Enzyme System; Half-Life; In Vitro Techniques | 1993 |
Sudden unexpected death in young adult due to right ventricular dysplasia.
Topics: Adult; Aging; Connective Tissue; Death, Sudden; Endocardium; Female; Forensic Medicine; Humans; Inci | 1997 |
Age might influence the frequency distribution of metoprolol hydroxylation polymorphism in a Chinese population.
Topics: Adolescent; Adult; Aged; Aging; China; Female; Gene Frequency; Humans; Hydroxylation; Male; Metoprol | 1997 |
Is the jejunal permeability in rats age-dependent?
Topics: Aging; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Atenolol; Glucose; Jejunum; Mal | 1997 |
Impaired isoproterenol-induced hyperpolarization in isolated mesenteric arteries of aged rats.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Age Factors; Aging; Animal | 1999 |
Orthostatic hypotension in aging humans.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Atropine; Blood Pressure; Female; Glycopyrrolate; H | 2000 |
Beta-adrenergic receptor blocking drugs in spontaneous hypertension.
Topics: Adrenergic beta-Antagonists; Aging; Alprenolol; Animals; Blood Pressure; Hypertension; Male; Metopro | 1976 |
Effects of beta-adrenoreceptor antagonists on sino-aortic baroreflex sensitivity and blood pressure in hypertensive man.
Topics: Acebutolol; Adolescent; Adrenergic beta-Agonists; Adult; Aging; Blood Pressure; Female; Heart Rate; | 1979 |
Plasma metoprolol concentrations in young, old and hypertensive subjects.
Topics: Adult; Aged; Aging; Blood Urea Nitrogen; Creatinine; Female; Humans; Hypertension; Male; Metoprolol; | 1977 |
Subsensitivity to beta-adrenoceptor agonists in pacemakers isolated from senescent rats.
Topics: Adrenergic beta-Agonists; Aging; Animals; Cocaine; Ethanolamines; Heart; Heart Rate; In Vitro Techni | 1991 |
The beta-adrenergic transduction system in kidneys from young and senescent rats.
Topics: Adenylyl Cyclase Inhibitors; Aging; Animals; Cyclic AMP; Guanylyl Imidodiphosphate; In Vitro Techniq | 1990 |
Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat.
Topics: Aging; Animals; Antipyrine; Atenolol; Male; Metabolic Clearance Rate; Metoprolol; Orosomucoid; Propr | 1990 |
Antihypertensive treatment in elderly hypertensives: implications of the MEHP study.
Topics: Aged; Aging; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Metoprolol; Middle Aged; | 1987 |
Beta-adrenoceptors and human skeletal muscle characterisation of receptor subtype and effect of age.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aging; Binding, Competitive; Female; Humans; M | 1989 |